MedTrace Logo

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

NCT00843375 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2026-05-11

No results posted yet for this study

Summary

Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy.

The purpose of this study if to determine if stool or blood can be used to detect colon cancers as early or earlier than colonoscopy. The researchers plan to use these samples to learn about specific proteins (also known as biomarkers) that may indicate colon polyps, colon cancer or an increased risk of developing colon cancer. In order to learn more about preventing and detecting colon and rectal cancer, we are collecting samples from subjects with cancer, adenomas, and colonoscopies who may be at risk for polyps.

Conditions

  • Colonic Neoplasms

Sponsors & Collaborators

  • Early Detection Research Network

    collaborator NETWORK

  • Clinical Genomics Pathology

    collaborator INDUSTRY

  • VolitionRx

    collaborator UNKNOWN

  • Department of Health and Human Services

    collaborator FED

  • Great Lakes New England Clinical Validation Center

    collaborator UNKNOWN

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Michigan Rogel Cancer Center

    lead OTHER

Principal Investigators

  • Dean E Brenner, M.D. · University of Michigan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-07
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00843375 on ClinicalTrials.gov